ADAPY (Adaptimmune Therapeutics) OCF Yield %: -2,710.80 (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics OCF Yield %?

Adaptimmune Therapeutics ADAPY +5.80% OCF Yield % is -2,710.80 as of Aug. 26, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Adaptimmune Therapeutics's Trailing 12-Month Cash Flow from Operations is $-190.03 Mil, and Market Cap is $7.01 Mil. Therefore, Adaptimmune Therapeutics's OCF Yield % for today is -2,710.80%.

The historical rank and industry rank for Adaptimmune Therapeutics's OCF Yield % or its related term are showing as below:

ADAPY' s OCF Yield % Range Over the Past 10 Years
Min: -47970.81   Med: -17.63   Max: 3.77
Current: -2710.8

During the past 13 years, the highest OCF Yield % of Adaptimmune Therapeutics was 3.77%. The lowest was -47970.81%. And the median was -17.63%.

ADAPY's OCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -8.24 vs ADAPY: -2710.80

Adaptimmune Therapeutics's OCF Margin % for the quarter that ended in Jun. 2025 was %.

Adaptimmune Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Adaptimmune Therapeutics OCF Yield % Related Terms

Adaptimmune Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics OCF Yield % Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.42 1.83 -59.02 -78.20 -53.10

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.06 -89.58 -99.23 -524.39 -218.97

ADAPY vs BCLI, APRE, JSPR: OCF Yield % Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's OCF Yield % falls into.


Adaptimmune Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Adaptimmune Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-73.206 / 137.8759554
=-53.10%

Adaptimmune Therapeutics's annualized OCF Yield % for the quarter that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-34.78 * 4 / 63.5329644
=-218.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -2,710.80 mean?
Adaptimmune Therapeutics (ADAPY) has a OCF Yield % of -2,710.80 as of Aug. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' OCF Yield % too high?
Adaptimmune Therapeutics' current OCF Yield % is -2,710.80.
How does Adaptimmune Therapeutics' OCF Yield % compare to BCLI and APRE?
Adaptimmune Therapeutics' OCF Yield % of -2,710.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current OCF Yield % is -2,710.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current OCF Yield % of -2,710.80. The current OCF Yield % is -2,710.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current OCF Yield % is -2,710.80 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].